Que recherchez-vous ?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published

Médicaments

Hero Banner Simple

 

Cosentyx® et vos patients

 

Identifier des profils patients qui pourraient être traités par Cosentyx® 

 

 

ACR: American College of Rheumatology ; CDLQI: Children’s Dermatology Life Quality Index ; DLQI: Dermatology Life Quality Index ; IGA: Investigator’s Global Assessment ; IC: intervalle de confiance ; IMC: indice de masse corporelle ; ITT: intention de traiter ; NAPSI: Nail Psoriasis Severity Index ; PASI : Psoriasis Area and Severity Index ; ppIGA: palmoplantar Ivestigator Global Assessment ; PSSI: Psoriasis Scalp Severity Index ; TNF: Tumor Necrosis Factor ; UVB: UltraViolet light B.

 

Références

  1. Blauvelt A, et al. Secukinumab is superior to Ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-9. e9. 

  2. HAS. Avis de la Commission de la Transparence du Produit Cosentyx® du 11 juillet 2022. 

  3. Langley RG, et al. ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326-38. Etude retenue lors de l’evaluation de l’AMM. 

  4. Résumé des Caractéristiques du Produit Cosentyx®. 

  5. Bissonnette R, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507-14. 

  6. Bagel J, et al. The effect of Secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667-74. 

  7. Gottlieb A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70-80. 

  8. Gottlieb AB, et al. Sustained efficacy of Secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2.5- year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020;182(4):889-99. 

  9. Reich K, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954-66. 

  10. Reich K, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425-36. 

  11. Bodemer C, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomised, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938-47. 

  12. Magnolo N, et al. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1):122-130. 

  13. HAS. Avis de la Commission de la Transparence du Produit Cosentyx® du 15 mars 2023. 

  14. Augustin M, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942-54.​ 

  15. Mease PJ, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression:primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890-7.​ 

  16. Van der Heijde D, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford). 2019;59(6):1325-34.​ 

  17. HAS. Avis de la Commission de la Transparence du Produit Cosentyx® du 22 juin 2016.​